Article info

Download PDFPDF

Extended report
Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial

Authors

  1. Correspondence to Dr Gerd R Burmester, Department of Rheumatology and Clinical Immunology, Charité—University Medicine Berlin, Free University and Humboldt University Berlin, Charitéplatz 1, Berlin 10117, Germany; Gerd.Burmester{at}charite.de
View Full Text

Citation

Burmester GR, Lin Y, Patel R, et al
Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial

Publication history

  • Received August 3, 2016
  • Revised October 13, 2016
  • Accepted October 15, 2016
  • First published November 17, 2016.
Online issue publication 
April 06, 2017

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.